Based in France, CARMAT is a startup. Brouky records 1 investor associated with the company.
CARMAT designs and develops an advanced artificial heart intended as a therapeutic alternative for patients with advanced biventricular heart failure. The company develops implantable cardiac devices to support or replace heart function.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.